Research programme: systemic RNAi therapeutics - Alnylam/Arbutus Biopharma
Alternative Names: TKM-ALDH2Latest Information Update: 04 Apr 2018
At a glance
- Originator Alnylam Pharmaceuticals; Tekmira Pharmaceuticals Corporation
- Developer Alnylam Pharmaceuticals; Arbutus Biopharma
- Class RNA
- Mechanism of Action Aldehyde dehydrogenase 2 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Cancer
Most Recent Events
- 16 Mar 2018 Arbutus has issued and pending patents for its therapeutic HBV product candidates and LNP delivery technology in countries worldwide
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alcoholism in Canada (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (IV)